no grade change (n = 24) | grade progression (n = 5) | p-value | |
---|---|---|---|
Clinical factors | |||
Age (yr), median (range) | 72.0 (62–90) | 76.0 (71–86) | 0.224 |
Performance Status (0/1/2) | 13/9/2 | 1/4/0 | 0.330 |
Severity of ILD (JRS) (1/2/3/4) | 9/7/4/4 | 0/3/2/0 | 0.434 |
mMRC scale (1/2/3/4/5) | 0/9/6/5/4 | 0/2/0/3/0 | 0.952 |
Tumor location (U/L) | 11/13 | 3/2 | 1.000 |
Tumor size (mm), median (range) | 34.0 (17–58) | 31.0 (22–63) | 0.544 |
serum KL-6, median (range) | 880.5 (325–2410) | 544.0 (466–1199) | 0.260 |
serum SP-D, median (range) | 152.0 (60–502) | 105.0 (31–140) | 0.036 |
Respiratory function, median (range) | |||
%VC | 90.7 (43.5–130.4) | 86.7 (64.9–107.3) | 0745 |
%FVC | 81.8 (37.9–117.6) | 82.7 (52.8–98.7) | 0.820 |
FEV1.0 (L) | 2.0 (1.13–2.92) | 2.0 (1.47–2.96) | 1.000 |
FEV1.0/VC (%) | 80.7 (54.0–91.2) | 78.6 (72.7–99.7) | 0.696 |
%DLco | 50.7 (15.5–92.2) | 70.7 (39–235.5) | 0.474 |
Not evaluated | 3 | 0 | |
Dose-volume metrics, median (range) | |||
PTV (mL) | 82.9 (34.6–345.9) | 88.1 (52.3–1319.8) | 0.507 |
Total dose (Gy[RBE]), | 52.8 (46–72) | 50.0 (50–72) | 0.5745 |
Dosimetric factors of the lung (%), median (range) | |||
V5 | 8.7 (3.0–20.6) | 14.2 (10.9–34.8) | 0.026 |
V10 | 7.6 (2.6–18.3) | 11.9 (8.4–32.8) | 0.033 |
V15 | 5.6 (2.2–13.6) | 8.0 (7.1–27.1) | 0.074 |
V20 | 5.0 (3.0–20.6) | 7.3 (6.2–18.0) | 0.069 |
V25 | 4.2 (1.8–11.0) | 5.4 (3.3–16.8) | 0.237 |
V30 | 3.7 (1.5–9.0) | 4.9 (2.8–15.9) | 0.286 |
V35 | 3.4 (1.4–8.5) | 4.4 (2.5–5.0) | 0.260 |
V40 | 3.1 (1.3–8.0) | 4.0 (2.2–14.0) | 0.260 |
Mean Lung Dose (Gy[RBE]) | 2.8 (1.0–6.4) | 3.8 (3.0–12.2) | 0.075 |